Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Sex Factors*; Antineoplastic Agents/*therapeutic use ; Carcinoma, Non-Small-Cell Lung/*drug therapy ; Lung Neoplasms/*drug therapy ; RNA, Long Noncoding/*metabolism ; RNA, Messenger/*metabolism; Adult ; Aged ; Bevacizumab/therapeutic use ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/metabolism ; Databases, Genetic ; Drug Resistance, Neoplasm ; Erlotinib Hydrochloride/therapeutic use ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Protein Interaction Maps ; Transcriptome ; Treatment Outcome

Background: While lung cancer patient outcomes are well-recognized to vary as a function of patient sex, there has been insufficient research regarding the relationship between patient sex and EGFR(Epidermal growth factor receptor) response efficacy. The present study therefore sought to identify novel sex-related biomarkers of bevacizumab/erlotinib (BE) responses in non-small cell lung cancer (NSCLC) patients.
Methods: The exon array data in the Gene Expression Omnibus (GEO) dataset were analyzed in order to identify patterns of mRNA and lncRNA expression associated with BE resistance in NSCLC. These differentially expressed (DE) lncRNAs and mRNAs were identified via DE Analysis Filtering. These DE mRNAs were then assessed for their potential functional roles via pathway enrichment analyses, with overlapping functions possibly associated with the BE resistance. The mRNAs in these overlapping groups were then assessed for their correlations with patient survival, and lncRNA-mRNA co-expression networks were generated for each patient subset. A protein-protein interaction (PPI) network was also generated based upon these DE mRNAs.
Results: In females we identified 172 DE lncRNAs and 1766 DE mRNAs associated with BE responses, while in males we identified 78 DE lncRNAs and 485 DE mRNAs associated with such responses. Based on the overlap between these two datasets, we identified a total of 37 GO functions and 18 pathways associated with BE responses. Co-expression and PPI networks suggested that the key lncRNAs and mRNAs associated with these BE response mechanisms weredifferent in the male and female patients.
Conclusions: This work is the first to conduct a global profiling of the relationship between lncRNA and mRNA expression patterns, patient sex, and BE responses in individuals suffering from NSCLC. Together these results suggest that the integrative lncRNA-mRNA expression analyses may offer invaluable new therapeutic insights that can guide the tailored treatment of lung cancer in order to ensure optimal BE responses.
Competing Interests: The authors have declared that no competing interests exist.

J Clin Oncol. 2013 Mar 10;31(8):1061-9. (PMID: 23401452)
Oncotarget. 2016 Dec 13;7(50):83735-83743. (PMID: 27863438)
Oncotarget. 2016 Apr 26;7(17):23197-211. (PMID: 26985770)
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11671-E11680. (PMID: 30487219)
PLoS One. 2013;8(2):e55637. (PMID: 23409011)
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. (PMID: 15329413)
Nat Rev Cancer. 2007 Mar;7(3):169-81. (PMID: 17318210)
Nat Rev Immunol. 2016 Oct;16(10):626-38. (PMID: 27546235)
Tuberc Respir Dis (Seoul). 2019 Jan;82(1):62-70. (PMID: 29926551)
Oncotarget. 2017 Oct 10;8(55):94440-94449. (PMID: 29212240)
J Cancer. 2020 Mar 5;11(11):3407-3415. (PMID: 32231747)
N Engl J Med. 2009 Sep 3;361(10):947-57. (PMID: 19692680)
N Engl J Med. 2005 Jul 14;353(2):123-32. (PMID: 16014882)
Genome Res. 2007 Oct;17(10):1537-45. (PMID: 17785539)
Cancer Discov. 2014 May;4(5):606-19. (PMID: 24535670)
Int J Cancer. 2019 Nov 15;145(10):2840-2849. (PMID: 30972745)
Clin Lung Cancer. 2018 Nov;19(6):e933-e944. (PMID: 30206043)
Oncotarget. 2016 Oct 11;7(41):67183-67195. (PMID: 27582538)
J Transl Med. 2018 Jul 9;16(1):191. (PMID: 29986714)
J Clin Oncol. 2011 Nov 1;29(31):4113-20. (PMID: 21969500)
Lancet Oncol. 2009 May;10(5):432-3. (PMID: 19410185)
Cancer Control. 2014 Jan;21(1):51-6. (PMID: 24357741)
N Engl J Med. 2009 Sep 3;361(10):958-67. (PMID: 19692684)
PLoS One. 2017 Jan 3;12(1):e0168550. (PMID: 28045923)
Lung Cancer. 2018 Aug;122:10-21. (PMID: 30032815)
Lancet. 2011 May 28;377(9780):1846-54. (PMID: 21621716)
Lung Cancer. 2012 Dec;78(3):239-44. (PMID: 23009726)
Lancet Oncol. 2019 May;20(5):625-635. (PMID: 30975627)
Curr Pharm Des. 2010;16(12):1410-6. (PMID: 20166984)
Lancet Oncol. 2018 Jun;19(6):737-746. (PMID: 29778737)
Gastroenterology. 2018 Nov;155(5):1309-1311. (PMID: 30300614)
Gastroenterology. 2018 Nov;155(5):1539-1552.e12. (PMID: 30063920)
Clin Transl Oncol. 2011 Sep;13(9):617-28. (PMID: 21865133)
Cell Biochem Funct. 2018 Dec;36(8):413-419. (PMID: 30379332)
Adv Drug Deliv Rev. 2015 Jun 29;87:15-24. (PMID: 26024979)
Lancet Oncol. 2010 Jun;11(6):521-9. (PMID: 20493771)
J Clin Oncol. 2013 Nov 1;31(31):3926-34. (PMID: 24101054)
J Nucl Med. 2012 Nov;53(11):1676-85. (PMID: 22984219)
Biosci Rep. 2019 Feb 5;39(2):. (PMID: 29769411)
Biochim Biophys Acta. 2015 Apr;1855(2):193-201. (PMID: 25598052)
J Thorac Oncol. 2013 Jul;8(7):823-59. (PMID: 23552377)
PLoS Comput Biol. 2008 Feb;4(2):e6. (PMID: 18463711)
Nat Rev Drug Discov. 2010 Nov;9(11):843-56. (PMID: 21031001)
Rev Invest Clin. 2013 Mar;65 Suppl 1:S5-84. (PMID: 24459776)
Cancer Cell. 2011 Apr 12;19(4):484-97. (PMID: 21481790)
Nat Rev Cancer. 2013 Apr;13(4):246-57. (PMID: 23467301)
J Transl Med. 2013 Apr 04;11:90. (PMID: 23557218)
J Natl Cancer Inst. 2019 Aug 1;111(8):772-781. (PMID: 31106827)

0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
0 (RNA, Long Noncoding)
0 (RNA, Messenger)
2S9ZZM9Q9V (Bevacizumab)
DA87705X9K (Erlotinib Hydrochloride)

Date Created: 20201019 Date Completed: 20201217 Latest Revision: 20201217

20240105

PMC7571718

10.1371/journal.pone.0240633

33075110